• Hiroto Tsuboi, Yuko Kaneko, Kei Ikeda, Toshihiko Aranishi, Zhihong Cai, and Tomoko Ishizuka.
• Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
• Curr Med Res Opin. 2022 May 1; 38 (5): 853-861.

ObjectiveTo assess the current status of shared decision making (SDM) in rheumatoid arthritis (RA) clinical practice in Japan from the perspectives of physicians and patients.MethodsA web-based survey was conducted to recruit patients with RA who were prescribed, for the first time, a conventional synthetic disease-modifying antirheumatic drug (csDMARD) or a biological drug/Janus kinase (JAK) inhibitor, and physicians who prescribed these treatments to patients with RA. The SDM Questionnaire-Physician version (SDM-Q-Doc) and the 9-item SDM Questionnaire (SDM-Q-9) were used to assess the SDM levels of physicians and patients, respectively. The scale ranged from 0 to 100, and higher scores indicated better SDM status.ResultsThe responses from 107 physicians who treat patients with RA, 107 patients prescribed a csDMARD, and 110 patients prescribed a biological drug/JAK inhibitor were collected. The mean SDM score for SDM-Q-Doc was 74.5 when physicians decided to prescribe a csDMARD and 77.2 when they decided to prescribe a biological drug/JAK inhibitor. However, the mean SDM score for SDM-Q-9 was 62.3 when patients were prescribed csDMARDs and 72.6 when they were prescribed biological drugs/JAK inhibitors.ConclusionsThe results showed differences in SDM level between patients and physicians and, from the patient perspective, between treatment types.

17 keywords...

hide…